期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

应用扩增的Treg预防异基因骨髓移植后移植物抗宿主病的实验研究 被引量：2

下载PDF
导出
摘要 目的:探讨扩增后的小鼠CD4+CD25+T细胞(Treg)输注对异基因骨髓移植(allo-BMT)后移植物抗宿主病(GVHD)的影响。方法:利用免疫磁珠法分选小鼠Treg细胞;以羊抗鼠CD3ε单抗、羊抗鼠CD28单抗、鼠重组IL-2及辐射过的BALB/c小鼠脾细胞为共刺激因子,扩增Treg细胞;建立C57BL/6→BALB/c小鼠allo-BMT模型,移植受鼠随机分为3组,移植后6～8h后分别予尾静脉输注扩增的Treg细胞、CD4+CD25-T细胞和RPMI1640培养液。以移植后GVHD表现,肝、脾、小肠组织病理形态、生存期为观察指标并进行组间比较。结果:经免疫磁珠法分选可获得高纯度(91.80±2.15)%及具较强活力(97.58±1.23)%的Treg细胞;移植后(4周左右)的扩增后Treg细胞移植组小鼠肝、脾、小肠GVHD病理损害较同期CD4+CD25-T细胞移植组与空白对照组小鼠有一定程度的减轻。3组小鼠移植后平均存活时间分别为(61.45±27.88)d、(18.58±12.39)d和(26.37±15.65)d,扩增后Treg细胞移植组小鼠平均存活时间较CD4+CD25-T细胞、空白对照组小鼠延长(P<0.05)。结论:allo-BMT后输注扩增的Treg细胞可以减轻移植后GVHD程度,延长小鼠生存时间。
作者 曹东林 陈伟 王玲
机构地区 南方医科大学基因工程研究所 广东省第二人民医院血液科
出处 《实用医学杂志》 CAS 2008年第20期3474-3476,共3页 The Journal of Practical Medicine
基金 广州市科技计划资助项目(编号:2005Z3-E0371)
关键词 移植物抗宿主病 T淋巴细胞 骨髓移植
分类号 R392 [医药卫生—免疫学]
  • 相关文献

参考文献9

  • 1Matsuoka K, Ichinohe T, Hashimoto D. Fetal tolerance to maternal antigens improves the outcome of altogeneic bone marrow transplantation by a CD4^+ CD25^+ T-cell-dependent mechanism [J]. Blood, 2006, 107( 1 ) :404-409.
  • 2Tanq Q, Henriksen K J, Bi M, et al. In vitro-expanded antigenspecific regulatory T cells suppress autoimmune diabetes [J]. J Exp Med, 2004,199( 11 ) : 1455-1465.
  • 3Teshima T, Ordemann R, Reddy P, et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium [J]. Nat Med, 2002,8 (6) : 575-581.
  • 4Cooke K R, Kobzik L, Martin T R, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: Ⅰ. The roles of minor H antigens and endotoxin [J]. Blood, 1996,8 (8) : 3230-3239.
  • 5Hoffmann P, Ermann J, Edinger M, et al. Donor-type CD4 (+) CD25 (+) regulatory T ceils suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation[J]. J Exp Med, 2002, 196(3) :389-399.
  • 6Taylor P A, Panoskaltsis-Mortari J M, Swedin P J, et al. LSelectinhi but not the LSelectinlo CD4^+25^+ T regulatory cells are potent inhibitors of GVHD and BM graft rejection [J]. Blood,2004,104(12) : 3804-3812.
  • 7Jones S C, Murphy G F, Korngold R, et al. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T ceils to allow an effective graft-versus-leukemia response [J]. Biol Blood Marrow Transplant, 2003, 9 (4) : 243 -256.
  • 8Edinger M, Hoffmann P, Ermann J, et al. CD4^+25^+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation [ J ].Nat Med, 2003,9 (9) : 1144-1150.
  • 9Trenado A, SuDres M, Tanq Q,et al. Ex vivo-expanded CD4^+CD25^+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells [J]. J Immunol, 2006,176(2) : 1266-1273.

同被引文献32

  • 1Baan C C,van der Mast B J,Klepper M,et al.Differential effect of calcineurin inhibitors,anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells[J].Transplantation,2005,80 (1):110-117.
  • 2Coenen J J,Koenen H J,van Rijssen E,et al.Rapamycin,and not cyclosporin A,preserves the highly suppressive CD27 + subset of human CD4+CD25+ regulatory T cells[J].Blood,2006,107(3):1018-1023.
  • 3Zhang H,Chua K S,Guimond M,et al.Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+ CD25+regulatory T cells[J].Nat Med,2005,11(11):1238-1243.
  • 4Pascual J,Bloom D,Torrealba J,et al.Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab:clinical outcomes and effect on T-regulatory cells[J].Am J Transplant,2008,8(7):1529-1536.
  • 5Bloom D D,Chang Z,Fechner J H,et al.CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H[J].Am J Transplant,2008,8(4):793-802.
  • 6Bluestone J A,LiuW,Yabu J M,et al.The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation[J].Am J Transplant,2008,8(10):2086-2096.
  • 7Gavin M A,Torgerson T R,Houston E,et al.Single-cell analysis of normal and FOXP3-mutant human T cells:FOXP3 expression without regulatory T cell development[J].Proc Natl Acad Sci U S A,2006,103 (17):6659-6664.
  • 8Roncarolo M G,Battaglia M.Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans[J].Nat Rev Immunol,2007,7(8):585-598.
  • 9Carrier Y,Yuan J,Kuchroo V K,et al.Th3 cells in peripheral tolerance.I.Induction of Foxp3-positive regulatory T cells by Th3 cells derived from TGF-beta T cell-transgenic mice[J].J Immunol,2007,178(1):179-185.
  • 10Joffre O,Santolaria T,Calise D,et al.Prevention of acute and chronic allograft rejection with CD4+CD25+ Foxp3+ regulatory T lymphocytes[J].Nat Med,2008,14(1):88-92.

引证文献2

二级引证文献2

实用医学杂志
2008年 第20期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部